Medical Policy
Preimplantation Genetic Testing

Document Number: 004

<table>
<thead>
<tr>
<th>Authorization required</th>
<th>Commercial* and Connector/ Qualified Health Plans</th>
<th>MassHealth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Notification within 24 hours or the next business day</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No notification or authorization</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not covered</td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

* Not all commercial plans cover this service, please check plan’s benefit package to verify coverage.

Overview
The purpose of this document is to describe the guidelines Neighborhood Health Plan (NHP) utilizes to determine medical appropriateness for preimplantation genetic testing (PGT) which includes preimplantation genetic diagnosis (PGD) for single gene defects and translocations, and preimplantation genetic screening (PGS) for aneuploidy.

Coverage Guidelines
NHP covers medically necessary PGD (and associated assisted reproductive services; e.g. IVF, ICSI) for a debilitating, genetically-defined and genetically predictable disease with early onset mortality or morbidity when there is no known treatment for the condition or the available interventions are either inadequately effective or significantly burdensome. NHP does not cover PGS.

The specialist and/or the primary care provider are responsible for providing all necessary clinical information including medical history of patient and partner or child, where appropriate. It is expected that the member/couple are counselled regarding the testing alternatives to PGD (e.g. amniocentesis, chorionic villous sampling), potential risks of PGD (embryo arrest, diagnostic uncertainly and unknown long-term effects of PGD), and that traditional prenatal diagnostic testing may still be recommended after successful PGD and pregnancy.

Authorization of PGD is limited to the following criteria:

Preimplantation Genetic Diagnosis (PGD)
1. NHP covers medically necessary PGD to test for unbalanced chromosome rearrangements when one of the genetic parents is known to have a balanced reciprocal translocation or Robertsonian translocation, or to have a microdeletion /duplication with one previously affected child. NHP may require laboratory documentation of the genetic tests.

2. NHP covers medically necessary PGD to detect evidence of any of the following genetic disorders in an embryo when:
   a. Both genetic parents are known carriers of a single gene autosomal recessive disorder, or one of the genetic parents is a known carrier and they have a child who has been diagnosed with the disorder such as, but not limited to the following:
      i. Canavan disease
      ii. Cystic Fibrosis
      iii. Epidermolysis Bullosa Simplex (autosomal recessive type)
      iv. Familial dysautonomia
      v. Fanconi’s Anemia
vi. Gaucher Disease  
 vii. Hurler Syndrome  
 viii. Methylmalonic acidemia  
ix. Propionic academia  
 x. Sickle Cell Anemia  
 xi. Spinal Muscular Atrophy Type I  
 xii. Spinocerebellar Ataxia (autosomal recessive type)  
 xiii. Tay-Sachs Disease  
 xiv. Thalassemia Syndromes  

b. One genetic parent is a known carrier of a single gene autosomal dominant disorder such as, but not limited to, the following:  
i. Epidermolysis Bullosa (autosomal dominant type)  
ii. Huntington’s Disease  
iii. Myotonic Dystrophy  
iv. Neurofibromatosis Type II  
v. Spinocerebellar Ataxia (autosomal dominant type)  
vi. Tuberous sclerosis  

c. The genetic female parent is a known carrier of a single gene X-linked recessive disorder such as, but not limited to the following:  
i. Adrenoleukodystrophy  
ii. Alport Syndrome  
iii. Becker muscular dystrophy  
iv. Fabry disease  
v. Choroideremia  
vi. Duchenne muscular dystrophy  
vi. Frangible X syndrome  
vii. Hemophilia A & B  
ix. Hunter Syndrome  
x. Incontinentia pigmenti  
xi. Lesch-Nyhan Syndrome  
xii. X-linked intellectual disability  

Exclusions  
 1. PGD services for any reason other than listed above.  
 2. PGD as an adjunct to infertility services for members who are not eligible for such services as determined by the Preimplantation Genetic Testing clinical coverage criteria.  
 3. PGD Services if the member or member’s spouse are using illicit substances or abusing substances known to negatively interfere with fertility or fetal development (e.g., marijuana, opiates, cocaine, or alcohol);  
 4. PGT for:  
a. Screening for aneuploidy including in the setting of: recurrent miscarriage, repeated failed implantation during IVF, or advanced maternal age.  
b. Screening for genetic or chromosomal abnormalities or traits in the absence of a known, clinically significant genetic or chromosomal condition in the genetic parents.  
c. Carrier testing to determine embryo’s carrier status.  
d. Human Leukocyte antigen (HLA) typing of an embryo to identify a future suitable stem cell, tissue or organ transplantation donor.  
e. Translocations which will always produce an abnormal gamete such as 45XX (21;21) & 45XY(21;21)  
f. Gender selection in the absence of a documented X-linked disorder.  
g. Selecting non-medical traits.  
h. Selecting against predisposition to disease when there is no single known genetic or chromosomal defect that definitively causes the disease.
Definitions

Autosomal Dominant: Autosomal dominant is one of several ways that a trait or disorder can be passed down through families. If a disease is autosomal dominant, it means you only need to get the abnormal gene from one parent in order for you to inherit the disease. One of the parents may often have the disease.

Autosomal Recessive: A disorder characterized by two mutated copies of the gene must be present in each cell in order for the disease or trait to develop. Affected persons usually have two unaffected parents who each carry a single copy of the mutated gene and they are known as carriers.

Preimplantation Genetic Diagnosis: A test involving an embryo that has been created using assisted reproductive technology such as in-vitro fertilization. After the eggs are removed the eggs are fertilized. Those eggs which are successfully fertilized are developed into a blastomere or a blastocyst. One or two cells are removed in order to test for the specific genetic condition in question.

X-linked Dominant Disorders: Caused by mutations in the gene on the X chromosome. Females are more frequently affected than males and the chances of passing on an X linked dominant disorder differ between men and women.

X-Linked Recessive: Are caused by mutations in the genes on the X chromosome. Males are more frequently affected than females and the chances of passing on the disorder differ between men and women. Families with an X linked recessive disorder often have affected males but rarely affected females in each generation. A characteristic of X linked inheritance is that fathers cannot pass X-linked traits to their sons.

CPT/HCPC Codes

<table>
<thead>
<tr>
<th>Authorized CPT/HCPCS Codes</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>89290</td>
<td>Biopsy, oocyte polar body or embryo blastomere, micro technique (for pre-implantation genetic diagnosis); less than or equal to 5 embryos</td>
</tr>
<tr>
<td>89291</td>
<td>Biopsy, oocyte polar body or embryo blastomere, micro technique (for pre-implantation genetic diagnosis); greater than 5 embryos</td>
</tr>
</tbody>
</table>

Effective

August 2018: Added language under item 1 subheading Preimplantation Genetic Diagnosis to include (and associated assisted reproductive services; e.g. IVF, ICSI).
April 2018: Annual update.
July 2017: Annual update. Added the exclusion “PGD Services if the member or member’s spouse are using illicit substances or abusing substances known to negatively interfere with fertility or fetal development (e.g., marijuana, opiates, cocaine, or alcohol)”
July 2016: Annual update
July 2015: Updated references
August 2014: Added language to Coverage Guidelines, “a debilitating genetic disease with early onset mortality or morbidity and when there is no known treatment for the condition or the available interventions are either inadequately effective or significantly burdensome.” Added exclusions: 3f selecting for non-medical traits and 3j Genetic conditions contributed to by donor egg and sperm.
June 2013: Annual update, added specific genetic disorders.
June 2012: Effective date.

References

doi: 10.1136/bmj.g7611

Checa, M., Alonso-Coello, P., Sola, I., Robles, A., Carreras, R & Balasch J., IVF/ICSI with or without preimplantation
genetic screening for aneuploidy in couples without genetic disorders: a systematic review and meta-analysis. J. Assist


Dahdouh EM, Balayla J et al., Impact of blastocyst biopsy and comprehensive chromosome screening
technology on preimplantation genetic screening: a systematic review of randomized controlled trials. Reproductive

Dahdouh EM, Balayla J et al., Preimplantation genetic screening using comprehensive chromosome screening: evidence

Ethics Committee of the American Society for Reproductive Medicine. Use of preimplantation genetic diagnosis for a

Franssen, M., Musters, A., Veen, V, et al., Reproductive outcome after PGD in couples with recurrent miscarriage

Franasiak JM, Forman EJ et al. The nature of aneuploidy with increasing age of the female partner: a review of 15,169
consecutive trophectoderm biopsies evaluated with comprehensive chromosomal screening. Fertil Steril 2014;101:656–
63.


2012 and 2015.

Ginsburg ES, Baker VL, et al., Use of preimplantation genetic diagnosis and preimplantation genetic screening in the

Gleicher, N., Kushnir, V., and Bard, D. Preimplantation genetic screening (PGS) still in search of a clinical application: a


Lee E, Illingworth P et al., The clinical effectiveness of preimplantation genetic diagnosis for aneuploidy in all 24

Liebaers, I., Desmyttere, S., Et Al. Report on consecutive series of 681 children born after blastomere biopsy for


Medicine 2007;357:9-17.